Cumberland Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Cumberland Pharmaceuticals shares (CPIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cumberland Pharmaceuticals employs 83 staff and has a trailing 12-month revenue of around $41.2 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $2.73 |
|---|---|
| 52-week range | $1.89 - $3.81 |
| 50-day moving average | $2.34 |
| 200-day moving average | $2.34 |
| Wall St. target price | $8.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.34 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.73 from 2023-01-27
| 1 week (2023-01-23) | 4.60% |
|---|---|
| 1 month (2022-12-30) | 21.33% |
| 3 months (2022-10-28) | 8.33% |
| 6 months (2022-07-29) | 20.26% |
| 1 year (2022-01-28) | -18.26% |
|---|---|
| 2 years (2021-01-29) | -13.88% |
| 3 years (2020-01-30) | 4.95 |
| 5 years (2018-01-30) | 6.935 |
| Revenue TTM | $41.2 million |
|---|---|
| Gross profit TTM | $27.2 million |
| Return on assets TTM | -5.45% |
| Return on equity TTM | -17.8% |
| Profit margin | -16.93% |
| Book value | $2.69 |
| Market capitalisation | $38.3 million |
TTM: trailing 12 months
We're not expecting Cumberland Pharmaceuticals to pay a dividend over the next 12 months.
Cumberland Pharmaceuticals's shares were split on a 2:1 basis on 5 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cumberland Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cumberland Pharmaceuticals shares which in turn could have impacted Cumberland Pharmaceuticals's share price.
Over the last 12 months, Cumberland Pharmaceuticals's shares have ranged in value from as little as $1.89 up to $3.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cumberland Pharmaceuticals's is 0.2689. This would suggest that Cumberland Pharmaceuticals's shares are less volatile than average (for this exchange).
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.